Innovent Biologics, Inc. announces that the company will deliver oral presentations on clinical data of its first-in-class PD-1/IL-2 bispecific antibody fusion protein and novel Topoi anti-Claudin18.2 ADC at the upcoming medical conferences in June, including ESMO Virtual Plenary and ESMO Gastrointestinal Cancers Congress 2024.
